A part of MilliporeSigma

Request Information

Parteck® SRP 80 Excipient for Sustained Release Solid Dose Formulations

Parteck® SRP 80 ExcipientsParteck® SRP 80, our new functional excipient based on polyvinyl alcohol (PVA), provides reliable sustained drug delivery over long release periods. Its matrix diffusion technology helps increase the efficacy and bioavailability of your compound while reducing side effects and the risk of dose dumping.

Parteck® SRP 80 is well suited for direct compression processes and helps accelerate your formulation work—from simplified feasibility and development to rapid and cost-efficient manufacturing.

Benefits of Parteck® SRP 80:

  • Reliable sustained release profiles of active pharmaceutical ingredients over several hours
  • Suitable for direct compression processes with conventional equipment
  • Resistant to pH- and alcohol-induced dose dumping
  • Superior batch-to-batch consistency and robust performance due to fully synthetic material
  • Faster time to market with the Emprove® program
Click hereto watch the video on Parteck® SRP 80.

For more detailed information about Parteck® SRP 80, see the flyer in the related resources section.


The Parteck® Game: Release the API. Play game now!

The Parteck® Game
Release the API

Play Game!
Your fast track through regulatory challenges. The new Emprove® program. Learn More

Your Fast Track Through Regulatory Challenges.
The new Emprove® program.

Learn More

Recent News

Oct 26, 2015
EMD Millipore Introduces Parteck® SRP 80 Excipient for Sustained-Release Oral Solid Dose Formulations

EMD Millipore today introduced Parteck® SRP 80, a new functional excipient for oral sustained-release formulations.

20151026 Small Molecule Pharmaceuticals,Biopharmaceutical Manufacturing
View All News